Vivani Medical (VANI) Insider Gregg Williams Buys $2M of Stock

Gregg Williams has made a substantial investment in VANI, purchasing 1,587,301 shares at an average price of $1.26 each on June 15, 2026. This transaction, not part of any pre-planned trading scheme, was valued at nearly $2 million.

Other Institutional Activity in VANI

Several institutional investors have also adjusted their positions in VANI. Vanguard Capital Management LLC added 1,530,933 shares, bringing its total to 1,530,933 shares, valued at approximately $1.53 million. UBS Group AG made a significant move by increasing its holdings by 331,035 shares, ending with 337,749 shares worth about $337,749. On the other hand, Tanager Wealth Management LLP reduced its stake by 98,075 shares, leaving it with 641,085 shares valued at $641,085. Geode Capital Management, LLC increased its holdings by 138,926 shares to a total of 600,578 shares, valued at $600,659.

Vivani Medical, Inc. Stock Up 0.8%

Shares of VANI are currently trading around $1.20. While specific financial metrics such as market cap and P/E ratio are not available, the stock's recent trading activity shows some volatility and interest from both insiders and institutional investors.

Insider Buying and Selling at Vivani Medical, Inc.

Gregg Williams has been actively purchasing VANI shares over the past several months. Notably, he bought 1,587,301 shares on both May 15, 2026, and June 15, 2026, at an average price of $1.26 per share. Earlier, in March, he acquired 1,575,231 shares at a slightly lower price of $1.07.

Analysts Set New Price Targets

On April 1, 2026, HC Wainwright & Co. maintained their buy rating for VANI, setting a price target of $3.5. This follows a series of consistent buy ratings from the firm, indicating a positive outlook for the stock. The consensus among analysts remains bullish, with VANI's prospects seen as promising.

Bottom Line

Gregg Williams' recent purchase of VANI shares underscores a strong commitment to the company. Institutional investors are also showing varied levels of interest, with some significantly increasing their stakes. Analysts maintain a positive outlook, with price targets suggesting upside potential. As always, it's essential to remember that insider transactions and analyst ratings reflect past actions and opinions, not future guarantees.